en · de · es · fr · pt
cardarine-notes.peptides6908.com › Blog › Preclinical Findings And Safety Signals — 2026 Update

Preclinical Findings And Safety Signals — 2026 Update

By Editorial Desk · published 2026-03-03 · last reviewed 2026-04-24 · Blog

Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

Related pages on this site

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Reference notes

=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.

=== Reassigned Codon Behavior === When codon reassignment occurs, it is usually due to a change in tRNAs. A tRNA can be assigned to a new codon or the tRNA can be altered to pick up a different amino acid. For the protein, this means either swapping one amino acid for another, or in the case of a stop codon, adding an amino acid where there was none before. Since the primary structure determines the functionality of a protein, changing even one amino acid in this way can drastically impact what the final protein is able to do.

Samples of water from the natural environment are routinely taken and analyzed as part of a pre-determined monitoring program by regulatory authorities to ensure that waters remain unpolluted, or if polluted, that the levels of pollution are not increasing or are falling in line with an agreed remediation plan. An example of such a scheme is the harmonized monitoring scheme operated on all the major river systems in the UK. The parameters analyzed will be highly dependent on nature of the local environment and/or the polluting sources in the area. In many cases the parameters will reflect the national and local water quality standards determined by law or other regulations. Typical parameters for ensuring that unpolluted surface waters remain within acceptable chemical standards include pH, major cations and anions including ammonia, nitrate, nitrite, phosphate, conductivity, phenol, chemical oxygen demand (COD) and biochemical oxygen demand (BOD).

Reptiles generally reproduce sexually, though some are capable of asexual reproduction. All reproductive activity occurs through the cloaca, the single exit/entrance at the base of the tail where waste is also eliminated. Most reptiles have copulatory organs, which are usually retracted or inverted and stored inside the body. In turtles and crocodilians, the male has a single median penis, while squamates, including snakes and lizards, possess a pair of hemipenes, only one of which is typically used in each session. Tuatara, however, lack copulatory organs, and so the male and female simply press their cloacas together as the male discharges sperm. Most reptiles lay amniotic eggs covered with leathery or calcareous shells. An amnion (5), chorion (6), and allantois (8) are present during embryonic life. The eggshell (1) protects the crocodile embryo (11) and keeps it from drying out, but it is flexible to allow gas exchange. The chorion (6) aids in gas exchange between the inside and outside of the egg. It allows carbon dioxide to exit the egg and oxygen gas to enter the egg. The albumin (9) further protects the embryo and serves as a reservoir for water and protein. The allantois (8) is a sac that collects the metabolic waste produced by the embryo. The amniotic sac (10) contains amniotic fluid (12) which protects and cushions the embryo. The amnion (5) aids in osmoregulation and serves as a saltwater reservoir.

Sources: en.wikipedia.org

Notes from published material

== Research == Her achievements include the discovery of adaptins, which are specific proteins that manage cell-trafficking to ensure the correct cell cargo is transported to the right location. She also discovered different combinations of adapting, when together with clathrin, form a coat around vesicles that bud from intracellular membranes and act as transporters for protein packages to be distributed in the cell. She also developed the technique "knock sideways," which inactivates proteins in seconds. After finishing her postdoc, she was able to start her own lab. Her main focus was to learn more about the AP protein in depth. She had to also work with DNA because in order to characterize the complexes thoroughly, she needed to clone the subunits. Robinson and her lab managed to find another AP complex, AP-3, which interacts with lysosomal membrane proteins such as LAMP1. AP-3 also interacts with tyrosinase, which is a key enzyme in melanin biosynthesis, so AP-3 is important for tyrosinase trafficking to premelanosomes. As of 2016 Robinson has a lab at Cambridge Institute for Medical Research. She specifically works with coated vesicles. The best-characterized coated vesicles are the clathrin-coated vesicles (CCVs). The coats on CCVs are primarily of clathrin, adaptor protein (AP) complexes, and alternative adaptors. Her working hypothesis is that for each trafficking pathway, there are a number of different adaptors, each of which is recruited independently onto the appropriate membrane.

On April 6, 2017, Pritzker announced his candidacy for the Democratic nomination for governor of Illinois. He was endorsed by Illinois Secretary of State Jesse White, Illinois Congressman Luis Gutiérrez, former Illinois Congressman Glenn Poshard, more than a dozen members of the Illinois General Assembly, 21 local labor unions, and the Illinois AFL–CIO. On August 10, 2017, Pritzker announced that his running mate would be freshman state representative and fellow Chicago resident Juliana Stratton. By December 2017, Pritzker had spent $42 million of his own money on his campaign without receiving funding from any other source. On March 20, 2018, he won the Democratic primary with 45.13% of the vote, defeating five opponents. On November 6, 2018, Pritzker defeated incumbent Republican governor Bruce Rauner in the general election, receiving 54.53% of the vote to Rauner's 38.83%. Pritzker was well ahead of Rauner in most polls from the summer of 2018 onward, and won by the largest margin in a gubernatorial race since 1994. Pritzker spent $171.5 million of his own money on his campaign, primarily on digital outreach, television advertising, and staff. Pritzker was inaugurated as Illinois's 43rd governor on January 14, 2019. With an estimated net worth of $3.6 billion in January 2019, he became the richest politician in the U.S. His second term in office began on January 9, 2023.

=== Operation Inherent Resolve === On 19 December 2014, Stars & Stripes, a daily military newspaper, announced 1,000 soldiers from the 82nd Airborne's 3rd Brigade Combat Team would deploy to Iraq to train, advise, and assist Iraq's Security Forces. On 3 November 2016, it was reported that 1,700 soldiers from the 2d Brigade Combat Team will deploy to the US Central Command area of responsibility in Iraq, to take part in Operation Inherent Resolve. They will replace the 2d Brigade Combat Team, 101st Airborne Division and will advise and assist Iraqi Security Forces currently trying to retake Mosul from ISIS fighters. On 27 March 2017, it was reported that 300 paratroopers from the 82nd Airborne's 2nd Brigade Combat Team will temporarily deploy to northern Iraq to provide additional advise-and-assist combating ISIS, particularly to speed up the offensive against ISIS in Mosul. On 31 December 2019, approximately 750 soldiers from the 82nd Airborne's Immediate Response Force were authorized to be deployed to Iraq in response to events which saw the United States' embassy in the country stormed. From the start of January 2017 to September 2017, the division suffered the loss of five paratroopers killed in action.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Network